Anders L Sørensen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2567059/publications.pdf

Version: 2024-02-01

933447 940533 16 402 10 16 citations g-index h-index papers 16 16 16 536 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Smoking impairs molecular response, and reduces overall survival in patients with chronic myeloproliferative neoplasms: A retrospective cohort study. British Journal of Haematology, 2021, 193, 83-92.	2.5	6
2	Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study. Redox Biology, 2021, 41, 101895.	9.0	8
3	The red blood cell count and the erythrocyte sedimentation rate in the diagnosis of polycythaemia vera. European Journal of Haematology, 2020, 104, 46-54.	2.2	5
4	Smoking, blood cells and myeloproliferative neoplasms: metaâ€analysis and Mendelian randomization of 2·3 million people. British Journal of Haematology, 2020, 189, 323-334.	2.5	27
5	Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. Haematologica, 2020, 105, 2262-2272.	3.5	67
6	Bâ€cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferonâ€Î±2, or combination treatment. European Journal of Haematology, 2019, 103, 351-361.	2.2	6
7	Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis?. Annals of Hematology, 2019, 98, 101-109.	1.8	7
8	Statin treatment, oxidative stress and inflammation in a Danish population. Redox Biology, 2019, 21, 101088.	9.0	44
9	JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation. Leukemia, 2019, 33, 995-1010.	7.2	43
10	Smoking is associated with increased risk of myeloproliferative neoplasms: A general populationâ€based cohort study. Cancer Medicine, 2018, 7, 5796-5802.	2.8	31
11	Safety and efficacy of combination therapy of interferonâ€Î±2 and ruxolitinib in polycythemia vera and myelofibrosis. Cancer Medicine, 2018, 7, 3571-3581.	2.8	38
12	Second malignancies in hydroxyurea and interferonâ€treated Philadelphiaâ€negative myeloproliferative neoplasms. European Journal of Haematology, 2017, 98, 75-84.	2.2	33
13	Smoking and philadelphiaâ€negative chronic myeloproliferative neoplasms. European Journal of Haematology, 2016, 97, 63-69.	2.2	36
14	Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia?. Leukemia and Lymphoma, 2016, 57, 1793-1799.	1.3	19
15	A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate. Leukemia Research Reports, 2016, 6, 20-23.	0.4	8
16	Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms. Leukemia Research, 2016, 41, 27-35.	0.8	24